News

Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension
Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for RN1871, a small interfering RNA (siRNA) drug ...
Yahoo Finance2d
Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension
SHANGHAI, April 21, 2025 /PRNewswire/ -- Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for ...
Pharmabiz1d
China NMPA approves Rona Therapeutics’ IND application for RN1871, a novel AGT-targeting siRNA drug for hypertension
China NMPA approves Rona Therapeutics’ IND application for RN1871, a novel AGT-targeting siRNA drug for hypertension: Shanghai, China Tuesday, April 22, 2025, 18:00 Hrs [IST] Ro ...
Le Lézard2d
ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio
Evogene Ltd. a leading computational biology company focused on revolutionizing life-science-based product discovery and ...
Le Lézard2d
4M Therapeutics to Present at the Upcoming American Psychological Association and American Society of Clinical Psychopharmacology Annual Meetings
M Therapeutics Inc. (4MTx), an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative diseases, today announced that the Company's CEO, Pablo Lapuerta, M.D.
Hosted on MSN23d
FORE Biotherapeutics to Present Plixorafenib Research at AACR Annual Meeting
The posters will feature contributions from leading oncologists, including Dr. Rona Yaeger of Memorial Sloan Kettering Cancer Center and Dr. Karisa Schreck of Johns Hopkins University, and will ...